netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
    • RESEARCH REPORTS
  • 2022 AGM NOTICE
  • CONTACT US

PDS Biotechnology Corporation liquidity funding program

Jul 31, 2019
-
News, PDS Biotechnology, RNS Announcements

31 July 2019

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014

NetScientific plc

(“NetScientific” or the “Company”)

PDS Biotechnology Corporation liquidity funding program

NetScientific plc (AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation (“PDS”) (Nasdaq:PDSB) has announced a liquidity funding program with Aspire Capital Fund, LLC (“Aspire”), an Illinois limited liability company, which has committed to purchase up to an aggregate of $20.0 million of shares of PDS common stock over the 30-month term of the Purchase Agreement dated 29 July 2019.

 

The liquidity funding program broadly provides that, on any trading day on which the price per share of PDS common stock exceeds US$0.50, selected by PDS at it sole discretion, that PDS can present Aspire with a purchase notice directing Aspire to purchase up to 100,000 shares of PDS’ common stock per business day (i) up to $20.0 million of the PDS’ common stock in aggregate and (ii) provided that Aspire’s aggregate interest in PDS does not exceed 19.99% of PDS’ issued common stock.

 

Such purchases shall be carried out at a per share price equal to the lesser of the lowest sale price of the PDS’ common stock on the purchase date; or the arithmetic average of the three lowest closing sale prices for PDS’ common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date.

 

Any proceeds PDS receives are expected to be used for working capital and general corporate purposes.

 

NetScientific holds 8.15% of PDS on a fully diluted basis.

 

The full details of the program can be found here: http://investors.pdsbiotech.com/financial-information/sec-filings

 

For more information, please contact:

 

 NetScientific

 Ian Postlethwaite, CEO / CFO

Tel: +44 (0)20 3514 1800

 WHIreland (NOMAD, Financial Adviser and   Broker)

 Chris Fielding / Jessica Cave

Tel: +44 (0)20 7220 1666

 MO PR ADVISORY (Press Contact)

 Mo Noonan

Tel: +44 (0)78 7644 4977

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
PDS second quarter 2019 financial results
NEXT POST →
Holding(s) in Company

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
Copyright
Terms of Use
PDS Biotechnology Corporation liquidity funding program - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT